| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Sr. VP & Chief Medical Officer
1 company
Nathalie Adda last filed a Form 4 in April 2022, as Sr. VP & Chief Medical Officer at ENTA. From February 2017 to April 2022, the filings on record show 0 open-market purchases and 12 sales. Nathalie Adda's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Nathalie Adda's trades have earned a strong insider score of 80/100 across 9 rated trades. Over a 12-month horizon, all 9 of those trades were profitable, with an average 12-month return of +37.7%.
At the last filing, the largest reported position was 34,982 shares of ENTA. The ENTA filings lean toward selling, a net 199,160 shares.
Shares as reported in the last Form 4 for each company; the most recent is from April 2022. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| May 16, 2018 | ENTA Enanta Pharmaceuticals Inc | Sr. VP & Chief Medical Officer | Sale+OE | 4,155 | $105.25 | $437,333.12 | -46.4% | |
| Apr 16, 2018 | ENTA Enanta Pharmaceuticals Inc | Sr. VP & Chief Medical Officer | Sale+OE | 4,225 | $85.58 | $361,559.68 | -41.3% |